NCT05203172 2026-03-18
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
Clinical Trials
12 trialsNCT06102902 2026-03-18
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05985954 2026-03-12
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT04324112 2025-11-10
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT06887088 2025-10-01
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT05706779 2025-09-02
NEORAF
Federation Francophone de Cancerologie Digestive
Phase 2 Recruiting
NCT07022457 2025-08-03
UK-EnBiRiM
Pierre Fabre Ltd
Recruiting
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting